Advertisement

Long-Term (≥10 Years) Safety of Percutaneous Treatment of Unprotected Left Main Stenosis With Drug-Eluting Stents

      Percutaneous coronary intervention (PCI) of unprotected left main disease (ULM) with drug-eluting stents (DES) is hampered by lack of information on long-term (≥10 years) safety data. All patients treated with PCI on ULM in 9 international centers with at least 10 years follow-up were enrolled. Baseline and procedural features were recorded. Repeat PCI (re-PCI) on ULM at 10 years was the primary end point. Secondary end points included major adverse cardiac events and its components (cardiac and noncardiac death, myocardial infarction, re-PCI not on ULM, and stent thrombosis). Sensitivity analysis was performed according to the presence of isolated ULM disease: 284 patients were enrolled. A total of 70 patients (21%) performed a re-PCI on ULM, 39 in the first year, and 31 between 1 and 10 years (only 5 overall performed for acute coronary syndrome). Patients with re-PCI on ULM did not show differences in baseline and procedural features, or experience higher rates of cardiovascular death (12% vs 11%, p 0.65), myocardial infarction (11% vs 6%, p 0.56), or of re-PCI on non-ULM disease (31% vs 27%, p 0.76) compared with those without re-PCI on ULM. At Kaplan–Meier analysis, patients with PCI in other coronary vessels were at higher risk of major adverse cardiac events, driven by target vessel revascularization (20.4% vs 32.9%, p 0.009), as confirmed at multivariate analysis (stenosis other than LM; hazard ratio 2, 1.4 to 2.7, all CI 95%). In conclusion, despite of using first-generation stents, PCI on ULM is safe, with low rates of recurrent events due to index revascularization. Progression of atherosclerotic lesions on other coronary vessels represents the only independent predictive factor for prognosis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Meliga E.
        • Garcia-Garcia H.M.
        • Valgimigli M.
        • Chieffo A.
        • Biondi-Zoccai G.
        • Maree A.O.
        • Cook S.
        • Reardon L.
        • Moretti C.
        • De S.S.
        • Palacios I.F.
        • Windecker S.
        • Colombo A.
        • van D.R.
        • Sheiban I.
        • Serruys P.W.
        Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (drug eluting stent for left main) registry.
        J Am Coll Cardiol. 2008; 51: 2212-2219
        • Mohr F.W.
        • Morice M.C.
        • Kappetein A.P.
        • Feldman T.E.
        • Stahle E.
        • Colombo A.
        • Mack M.J.
        • Holmes Jr., D.R.
        • Morel M.A.
        • Van D.N.
        • Houle V.M.
        • Dawkins K.D.
        • Serruys P.W.
        Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.
        Lancet. 2013; 381: 629-638
        • Naganuma T.
        • Chieffo A.
        • Meliga E.
        • Capodanno D.
        • Park S.J.
        • Onuma Y.
        • Valgimigli M.
        • Jegere S.
        • Makkar R.R.
        • Palacios I.F.
        • Costopoulos C.
        • Kim Y.H.
        • Buszman P.P.
        • Chakravarty T.
        • Sheiban I.
        • Mehran R.
        • Naber C.
        • Margey R.
        • Agnihotri A.
        • Marra S.
        • Capranzano P.
        • Leon M.B.
        • Moses J.W.
        • Fajadet J.
        • Lefevre T.
        • Morice M.C.
        • Erglis A.
        • Tamburino C.
        • Alfieri O.
        • Serruys P.W.
        • Colombo A.
        Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
        JACC Cardiovasc Interv. 2013; 6: 1242-1249
        • Sheiban I.
        • Sillano D.
        • Biondi-Zoccai G.
        • Chieffo A.
        • Colombo A.
        • Vecchio S.
        • Margheri M.
        • Gunn J.P.
        • Raina T.
        • Liistro F.
        • Bolognese L.
        • Lee M.S.
        • Tobis J.
        • Moretti C.
        Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study).
        J Am Coll Cardiol. 2009; 54: 1131-1136
        • Windecker S.
        • Kolh P.
        • Alfonso F.
        • Collet J.P.
        • Cremer J.
        • Falk V.
        • Filippatos G.
        • Hamm C.
        • Head S.J.
        • Juni P.
        • Kappetein A.P.
        • Kastrati A.
        • Knuuti J.
        • Landmesser U.
        • Laufer G.
        • Neumann F.J.
        • Richter D.J.
        • Schauerte P.
        • Sousa U.M.
        • Stefanini G.G.
        • Taggart D.P.
        • Torracca L.
        • Valgimigli M.
        • Wijns W.
        • Witkowski A.
        2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
        Eur Heart J. 2014; 35: 2541-2619
      1. Syntaxscore. www syntaxscore com.

        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • Van Es G.A.
        • Steg P.G.
        • Morel M.A.
        • Mauri L.
        • Vranckx P.
        • McFadden E.
        • Lansky A.
        • Hamon M.
        • Krucoff M.W.
        • Serruys P.W.
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • D'Ascenzo F.
        • Cavallero E.
        • Biondi-Zoccai G.
        • Moretti C.
        • Omede P.
        • Bollati M.
        • Castagno D.
        • Modena M.G.
        • Gaita F.
        • Sheiban I.
        Use and misuse of multivariable approaches in interventional cardiology studies on drug-eluting stents: a systematic review.
        J Interv Cardiol. 2012; 25: 611-621
        • Ahn J.M.
        • Roh J.H.
        • Kim Y.H.
        • Park D.W.
        • Yun S.C.
        • Lee P.H.
        • Chang M.
        • Park H.W.
        • Lee S.W.
        • Lee C.W.
        • Park S.W.
        • Choo S.J.
        • Chung C.
        • Lee J.
        • Lim D.S.
        • Rha S.W.
        • Lee S.G.
        • Gwon H.C.
        • Kim H.S.
        • Chae I.H.
        • Jang Y.
        • Jeong M.H.
        • Tahk S.J.
        • Seung K.B.
        • Park S.J.
        Randomized trial of stents versus bypass surgery for left main coronary artery disease: 5-Year outcomes of the PRECOMBAT study.
        J Am Coll Cardiol. 2015; 65: 2198-2206
        • Lee M.S.
        • Stone G.W.
        • Park S.J.
        • Teirstein P.
        • Moses J.
        • Colombo A.
        • Kandzari D.E.
        Percutaneous coronary intervention of unprotected left main coronary artery disease: procedural strategies and technical considerations.
        Catheter Cardiovasc Interv. 2012; 79: 812-822
        • Biondi-Zoccai G.G.
        • Giraudi E.
        • Moretti C.
        • Sciuto F.
        • Omede P.
        • Sillano D.
        • Garrone P.
        • Trevi G.P.
        • Sheiban I.
        Impact of routine angiographic follow-up after percutaneous coronary drug-eluting stenting for unprotected left main disease: the Turin Registry.
        Clin Res Cardiol. 2010; 99: 235-242
        • Morice M.C.
        • Serruys P.W.
        • Kappetein A.P.
        • Feldman T.E.
        • Stahle E.
        • Colombo A.
        • Mack M.J.
        • Holmes D.R.
        • Torracca L.
        • Van Es G.A.
        • Leadley K.
        • Dawkins K.D.
        • Mohr F.
        Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial.
        Circulation. 2010; 121: 2645-2653
        • Damgaard S.
        • Steinbruchel D.A.
        • Kjaergard H.K.
        An update on internal mammary artery grafting for coronary artery disease.
        Curr Opin Cardiol. 2005; 20: 521-524
        • Yusuf S.
        • Zucker D.
        • Peduzzi P.
        • Fisher L.D.
        • Takaro T.
        • Kennedy J.W.
        • Davis K.
        • Killip T.
        • Passamani E.
        • Norris R.
        Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.
        Lancet. 1994; 344: 563-570
        • Zeff R.H.
        • Kongtahworn C.
        • Iannone L.A.
        • Gordon D.F.
        • Brown T.M.
        • Phillips S.J.
        • Skinner J.R.
        • Spector M.
        Internal mammary artery versus saphenous vein graft to the left anterior descending coronary artery: prospective randomized study with 10-year follow-up.
        Ann Thorac Surg. 1988; 45: 533-536
        • D'Ascenzo F.
        • Colombo F.
        • Barbero U.
        • Moretti C.
        • Omede P.
        • Reed M.J.
        • Tarantini G.
        • Frati G.
        • Di Nicolantonio J.J.
        • Biondi Z.G.
        • Gaita F.
        Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis.
        J Interv Cardiol. 2014; 27: 233-241
        • D'Ascenzo F.
        • Barbero U.
        • Cerrato E.
        • Lipinski M.J.
        • Omede P.
        • Montefusco A.
        • Taha S.
        • Naganuma T.
        • Reith S.
        • Voros S.
        • Latib A.
        • Gonzalo N.
        • Quadri G.
        • Colombo A.
        • Biondi-Zoccai G.
        • Escaned J.
        • Moretti C.
        • Gaita F.
        Accuracy of intravascular ultrasound and optical coherence tomography in identifying functionally significant coronary stenosis according to vessel diameter: a meta-analysis of 2,581 patients and 2,807 lesions.
        Am Heart J. 2015; 169: 663-673
        • Palmerini T.
        • Biondi-Zoccai G.
        • Della R.D.
        • Stettler C.
        • Sangiorgi D.
        • D'Ascenzo F.
        • Kimura T.
        • Briguori C.
        • Sabate M.
        • Kim H.S.
        • De W.A.
        • Kedhi E.
        • Smits P.C.
        • Kaiser C.
        • Sardella G.
        • Marullo A.
        • Kirtane A.J.
        • Leon M.B.
        • Stone G.W.
        Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
        Lancet. 2012; 379: 1393-1402
        • Novara M.
        • D'Ascenzo F.
        • Gonella A.
        • Bollati M.
        • Biondi-Zoccai G.
        • Moretti C.
        • Omedè P.
        • Sciuto F.
        • Sheiban I.
        • Gaita F.
        Changing of SYNTAX score performing fractional flow reserve in multivessel coronary artery disease.
        J Cardiovasc Med (Hagerstown). 2012; 13: 368-375

      Linked Article